Literature DB >> 32291723

Opioid Agonist Therapy During Hospitalization Within the Veterans Health Administration: a Pragmatic Retrospective Cohort Analysis.

Kelsey C Priest1,2, Travis I Lovejoy3,4,5, Honora Englander6, Sarah Shull5, Dennis McCarty3.   

Abstract

BACKGROUND: Hospitalization of patients with opioid use disorder (OUD) is increasing, yet little is known about opioid agonist therapy (OAT: methadone and buprenorphine) administration during admission.
OBJECTIVE: Describe and examine patient- and hospital-level characteristics associated with OAT receipt during hospitalization in the Veterans Health Administration (VHA). PARTICIPANTS: A total of 12,407 unique patients, ≥ 18 years old, with an OUD-related ICD-10 diagnosis within 12 months prior to or during index hospitalization in fiscal year 2017 from 109 VHA hospitals in the continental U.S. MAIN MEASURE: OAT received during hospitalization. KEY
RESULTS: Few admissions received OAT (n = 1914; 15%) and when provided it was most often for withdrawal management (n = 834; 7%). Among patients not on OAT prior to admission who survived hospitalization (n = 10,969), 2.0% (n = 203) were newly initiated on OAT with linkage to care after hospital discharge. Hospitals varied in the frequency of OAT delivery (range, 0 to 43% of qualified admissions). Patients with pre-admission OAT (adjusted odds ratio [AOR] = 15.30; 95% CI [13.2, 17.7]), acute OUD diagnosis (AOR = 2.3; 95% CI [1.99, 2.66]), and male gender (AOR 1.52; 95% CI [1.16, 2.01]) had increased odds of OAT receipt. Patients who received non-OAT opioids (AOR 0.53; 95% CI [0.46, 0.61]) or surgical procedures (AOR 0.75; 95% CI [0.57, 0.99]) had decreased odds of OAT receipt. Large-sized (AOR = 2.0; 95% CI [1.39, 3.00]) and medium-sized (AOR = 1.9; 95% CI [1.33, 2.70]) hospitals were more likely to provide OAT.
CONCLUSIONS: In a sample of VHA inpatient medical admissions, OAT delivery was infrequent, varied across the health system, and was associated with specific patient and hospital characteristics. Policy and educational interventions should promote hospital-based OAT delivery.

Entities:  

Keywords:  buprenorphine; hospital medicine; methadone; opioid agonist therapy; opioid use disorder

Mesh:

Substances:

Year:  2020        PMID: 32291723      PMCID: PMC7403377          DOI: 10.1007/s11606-020-05815-0

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  25 in total

1.  Possible Alternatives to Diagnosis-Based Denominators for Addiction Treatment Quality Measures.

Authors:  Alex H S Harris; Anna D Rubinsky; Katherine J Hoggatt
Journal:  J Subst Abuse Treat       Date:  2015-06-19

2.  Biased labels: An experimental study of language and stigma among individuals in recovery and health professionals.

Authors:  Robert D Ashford; Austin M Brown; Jessica McDaniel; Brenda Curtis
Journal:  Subst Use Misuse       Date:  2019-04-04       Impact factor: 2.164

3.  Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: Historical perspective, lessons learned, and next steps.

Authors:  Jessica J Wyse; Adam J Gordon; Steven K Dobscha; Benjamin J Morasco; Elizabeth Tiffany; Karen Drexler; Friedhelm Sandbrink; Travis I Lovejoy
Journal:  Subst Abus       Date:  2018       Impact factor: 3.716

4.  Receipt of opioid agonist treatment in the Veterans Health Administration: facility and patient factors.

Authors:  Elizabeth M Oliva; Alex H S Harris; Jodie A Trafton; Adam J Gordon
Journal:  Drug Alcohol Depend       Date:  2011-11-23       Impact factor: 4.492

5.  Predictors of substance use treatment initiation and engagement among adult and adolescent Medicaid recipients.

Authors:  Bonnie K Lind; Dennis McCarty; Yifan Gu; Robin Baker; K John McConnell
Journal:  Subst Abus       Date:  2019-02-13       Impact factor: 3.716

6.  Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science.

Authors:  Andrea K Finlay; Ingrid A Binswanger; Christine Timko; David Smelson; Matthew A Stimmel; Mengfei Yu; Tom Bowe; Alex H S Harris
Journal:  J Subst Abuse Treat       Date:  2018-10-02

7.  "It's been an Experience, a Life Learning Experience": A Qualitative Study of Hospitalized Patients with Substance Use Disorders.

Authors:  Christine M Velez; Christina Nicolaidis; P Todd Korthuis; Honora Englander
Journal:  J Gen Intern Med       Date:  2016-12-12       Impact factor: 5.128

8.  "Now hospital leaders are paying attention": A qualitative study of internal and external factors influencing addiction consult services.

Authors:  Kelsey C Priest; Honora Englander; Dennis McCarty
Journal:  J Subst Abuse Treat       Date:  2019-12-05

9.  "We've Learned It's a Medical Illness, Not a Moral Choice": Qualitative Study of the Effects of a Multicomponent Addiction Intervention on Hospital Providers' Attitudes and Experiences.

Authors:  Honora Englander; Devin Collins; Sylvia Peterson Perry; Molly Rabinowitz; Elena Phoutrides; Christina Nicolaidis
Journal:  J Hosp Med       Date:  2018-04-25       Impact factor: 2.960

10.  Inpatient Addiction Medicine Consultation and Post-Hospital Substance Use Disorder Treatment Engagement: a Propensity-Matched Analysis.

Authors:  Honora Englander; Konrad Dobbertin; Bonnie K Lind; Christina Nicolaidis; Peter Graven; Claire Dorfman; P Todd Korthuis
Journal:  J Gen Intern Med       Date:  2019-12       Impact factor: 5.128

View more
  18 in total

1.  Expanding the Team: Optimizing the Multidisciplinary Management of Drug Use-Associated Infective Endocarditis.

Authors:  Matthew O'Donnell; Honora Englander; Luke Strnad; Castigliano M Bhamidipati; Evan Shalen; Patricio A Riquelme
Journal:  J Gen Intern Med       Date:  2022-01-11       Impact factor: 5.128

2.  Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines.

Authors:  Susan L Calcaterra; Richard Bottner; Marlene Martin; Honora Englander; Zoe M Weinstein; Melissa B Weimer; Eugene Lambert; Matthew V Ronan; Sergio Huerta; Tauheed Zaman; Monish Ullal; Alyssa F Peterkin; Kristine Torres-Lockhart; Megan Buresh; Meghan T O'Brien; Hannah Snyder; Shoshana J Herzig
Journal:  J Hosp Med       Date:  2022-07-26       Impact factor: 2.899

3.  Causes of Death in the 12 Months After Hospital Discharge Among Patients With Opioid Use Disorder.

Authors:  Caroline King; Ryan Cook; P Todd Korthuis; Cynthia D Morris; Honora Englander
Journal:  J Addict Med       Date:  2021-09-10       Impact factor: 4.647

4.  Expanding Inpatient Addiction Consult Services Through Accountable Care Organizations for Medicaid Enrollees: A Modeling Study.

Authors:  Caroline A King; Ryan Cook; P Todd Korthuis; Dennis McCarty; Cynthia D Morris; Honora Englander
Journal:  J Addict Med       Date:  2022-02-08       Impact factor: 4.647

5.  Long-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study.

Authors:  Joshua A Barocas; Golnaz Eftekhari Yazdi; Alexandra Savinkina; Shayla Nolen; Caroline Savitzky; Jeffrey H Samet; Honora Englander; Benjamin P Linas
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

6.  Recognizing and Reducing the Impact of Trauma of Hospitalization: Considerations for Persons Who Use Drugs.

Authors:  John C Messinger; Joji Suzuki
Journal:  J Addict Med       Date:  2022 Jan-Feb 01       Impact factor: 3.702

7.  Hospital policies for opioid use disorder treatment: A policy content analysis and environmental scan checklist.

Authors:  Kelsey C Priest; Honora Englander; Dennis McCarty
Journal:  Gen Hosp Psychiatry       Date:  2021-02-22       Impact factor: 3.238

8.  A Resident-Led Intervention to Increase Initiation of Buprenorphine Maintenance for Hospitalized Patients With Opioid Use Disorder.

Authors:  Ashish P Thakrar; David Furfaro; Sara Keller; Ryan Graddy; Megan Buresh; Leonard Feldman
Journal:  J Hosp Med       Date:  2021-06       Impact factor: 2.899

9.  Interventions for hospitalized medical and surgical patients with opioid use disorder: A systematic review.

Authors:  Rachel French; Shoshana V Aronowitz; J Margo Brooks Carthon; Heath D Schmidt; Peggy Compton
Journal:  Subst Abus       Date:  2021-07-20       Impact factor: 3.984

10.  Impact of medications for opioid use disorder among persons hospitalized for drug use-associated skin and soft tissue infections.

Authors:  Joshua A Barocas; Mam Jarra Gai; Brenda Amuchi; Raagini Jawa; Benjamin P Linas
Journal:  Drug Alcohol Depend       Date:  2020-08-01       Impact factor: 4.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.